WEST LAFAYETTE, Ind., March 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing
targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the
company’s management team will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March
8th at 8:00 a.m. EST. The conference is being held at the Boston Marriott Copley Place.
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and
other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging
agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased
cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active
drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug
alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy
and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at
www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, stephanie@sternir.com
